接受免疫治疗的晚期非小细胞肺癌患者体成分分析
该多队列分析纳入1791例晚期或转移性非小细胞肺癌患者,评估体成分与肿瘤结局的关联。骨骼肌质量下降与总生存期和无进展生存期较差相关,尤其在男性患者中更明显;皮下脂肪组织密度增加超过5%与较差总生存期相关,主要在女性患者中观察到。作者认为自动CT衍生的体成分测量可考虑用于判断非小细胞肺癌预后。
要点
- 骨骼肌质量下降与接受免疫治疗的晚期非小细胞肺癌患者总生存期和无进展生存期较差相关。
- 皮下脂肪组织密度增加超过5%与3个队列较差总生存期相关,主要在女性患者中观察到。
- 作者认为自动CT衍生的体成分测量可考虑用于判断非小细胞肺癌预后。
核心结论
- 该系统治疗期间骨骼肌质量下降是非小细胞肺癌预后不良的标志,尤其在男性患者中。
- 皮下脂肪组织密度变化也与预后相关,尤其在女性患者中。
- 作者认为自动CT衍生的体成分测量可考虑用于判断非小细胞肺癌预后。
研究设计与样本
- 该多队列分析纳入1791例非小细胞肺癌患者(878例女性,占49%),其中487例(27.2%)在Dana-Farber Brigham癌症中心接受化疗免疫治疗(DFBCC-CIO),825例(46.1%)在该中心接受免疫检查点抑制剂单药治疗(DFBCC-IO),222例(12.4%)在1/2期Study 1108中接受度伐利尤单抗单药治疗,257例(14.3%)在3期MYSTIC试验化疗组接受化疗。
- 各队列中位(IQR)年龄分别为65(58-74)岁、66(57-71)岁、65(26-87)岁和63(30-84)岁。
- 收集基线和随访CT扫描,使用深度神经网络自动选择L3层面并分割体成分(骨骼肌、皮下脂肪组织和内脏脂肪组织),根据基线体成分测量值或首次随访扫描时的变化比较结局。
- 数据分析时间为2022年7月至2023年4月。
主要发现
- 骨骼肌质量下降与多个患者群体的肿瘤结局较差相关:DFBCC-CIO队列总生存期HR为0.59(95%CI,0.43-0.81),无进展生存期HR为0.61(95%CI,0.47-0.79);DFBCC-IO队列总生存期HR为0.74(95%CI,0.60-0.91);Study 1108总生存期HR为0.46(95%CI,0.33-0.64),无进展生存期HR为0.47(95%CI,0.34-0.64);MYSTIC试验无进展生存期HR为0.76(95%CI,0.61-0.96)。
- Kaplan-Meier分析显示,该关联在男性患者中最明显,在MYSTIC试验和DFBCC-CIO队列的女性患者中关联不显著。
- 皮下脂肪组织密度增加超过5%与3个患者队列较差总生存期相关:DFBCC-CIO队列HR为0.61(95%CI,0.43-0.86);DFBCC-IO队列HR为0.62(95%CI,0.49-0.79);Study 1108 HR为0.56(95%CI,0.40-0.77)。
- 皮下脂肪组织密度变化也与DFBCC-CIO队列无进展生存期相关(HR,0.73;95%CI,0.54-0.97),Kaplan-Meier分析主要在女性患者中观察到。
临床怎么用
- 作者认为,自动CT衍生的体成分测量可考虑用于判断非小细胞肺癌预后。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The association between body composition (BC) and cancer outcomes is complex and incompletely understood. Previous research in non-small-cell lung cancer (NSCLC) has been limited to small, single-institution studies and yielded promising, albeit heterogeneous, results. OBJECTIVES: To evaluate the association of BC with oncologic outcomes in patients receiving immunotherapy for advanced or metastatic NSCLC. DESIGN, SETTING, AND PARTICIPANTS: This comprehensive multicohort analysis included clinical data from cohorts receiving treatment at the Dana-Farber Brigham Cancer Center (DFBCC) who received immunotherapy given alone or in combination with chemotherapy and prospectively collected data from the phase 1/2 Study 1108 and the chemotherapy arm of the phase 3 MYSTIC trial. Baseline and follow-up computed tomography (CT) scans were collected and analyzed using deep neural networks for automatic L3 slice selection and body compartment segmentation (skeletal muscle [SM], subcutaneous adipose tissue [SAT], and visceral adipose tissue). Outcomes were compared based on baseline BC measures or their change at the first follow-up scan. The data were analyzed between July 2022 and April 2023. MAIN OUTCOMES AND MEASURES: Hazard ratios (HRs) for the association of BC measurements with overall survival (OS) and progression-free survival (PFS). RESULTS: A total of 1791 patients (878 women [49%]) with NSCLC were analyzed, of whom 487 (27.2%) received chemoimmunotherapy at DFBCC (DFBCC-CIO), 825 (46.1%) received ICI monotherapy at DFBCC (DFBCC-IO), 222 (12.4%) were treated with durvalumab monotherapy on Study 1108, and 257 (14.3%) were treated with chemotherapy on MYSTIC; median (IQR) ages were 65 (58-74), 66 (57-71), 65 (26-87), and 63 (30-84) years, respectively. A loss in SM mass, as indicated by a change in the L3 SM area, was associated with worse oncologic outcome across patient groups (HR, 0.59 [95% CI, 0.43-0.81] and 0.61 [95% CI, 0.47-0.79] for OS and PFS, respectively, in DFBCC-CIO; HR, 0.74 [95% CI, 0.60-0.91] for OS in DFBCC-IO; HR, 0.46 [95% CI, 0.33-0.64] and 0.47 [95% CI, 0.34-0.64] for OS and PFS, respectively, in Study 1108; HR, 0.76 [95% CI, 0.61-0.96] for PFS in the MYSTIC trial). This association was most prominent among male patients, with a nonsignificant association among female patients in the MYSTIC trial and DFBCC-CIO cohorts on Kaplan-Meier analysis. An increase of more than 5% in SAT density, as quantified by the average CT attenuation in Hounsfield units of the SAT compartment, was associated with poorer OS in 3 patient cohorts (HR, 0.61 [95% CI, 0.43-0.86] for DFBCC-CIO; HR, 0.62 [95% CI, 0.49-0.79] for DFBCC-IO; and HR, 0.56 [95% CI, 0.40-0.77] for Study 1108). The change in SAT density was also associated with PFS for DFBCC-CIO (HR, 0.73; 95% CI, 0.54-0.97). This was primarily observed in female patients on Kaplan-Meier analysis. CONCLUSIONS AND RELEVANCE: The results of this multicohort study suggest that loss in SM mass during systemic therapy for NSCLC is a marker of poor outcomes, especially in male patients. SAT density changes are also associated with prognosis, particularly in female patients. Automated CT-derived BC measurements should be considered in determining NSCLC prognosis.
引用
- Chaunzwa TL, Qian JM, Li Q, et al. Body Composition in Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy. JAMA Oncol. 2024. PMID: 38780929. doi:10.1001/jamaoncol.2024.1120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。